Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes

BACKGROUND: Interleukin-6 (IL-6) is a pleiotropic cytokine that plays a key role in the pathogenesis of rheumatoid arthritis. Sarilumab is a human monoclonal antibody that binds membrane-bound and soluble IL-6 receptor-α to inhibit IL-6 signalling. The aim of this study was to compare the effects of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Arthritis Res Ther
Main Authors: Gabay, Cem, Burmester, Gerd R., Strand, Vibeke, Msihid, Jérôme, Zilberstein, Moshe, Kimura, Toshio, van Hoogstraten, Hubert, Boklage, Susan H., Sadeh, Jonathan, Graham, Neil M. H., Boyapati, Anita
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7137491/
https://ncbi.nlm.nih.gov/pubmed/32264972
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-020-02163-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados